NCT02788877 - Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 10, 2016

Primary Completion Date

September 30, 2019

Study Completion Date

December 31, 2019

Conditions

Macular Edema, Diabetic

Interventions

DRUG

aflibercept

Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30 gauge needle-attached syringe.

Trial Locations (8)

Gyeongsang National University Hospital, Jinju

Gospel Hospital, Busan

Pusan National University Hospital, Busan

Haeundae Paik Hospital, Busan

Busan Paik Hospital, Busan

Yeungnam University Medical Center, Daegu

Keimyung University Dongsan Medical Center, Daegu

Kyungpook National University Hospital, Daegu